Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANT-301 in knee osteoarthritis
NCT06539429Phase 1Active, not recruiting
- Sponsor
- Anterogen Co., Ltd.
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ANT-301 in osteoarthritis (OA), sponsored by Anterogen Co., Ltd. Primary endpoint: Safety Assessment at 12 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
ANT-301
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06539429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539429.